Overall, our results suggest that the combined treatment of ENB101-LNP and cisplatin not only inhibits cell proliferation but also enhances HLA-A expression, promoting antigen presentation and stimulating an immune response against cervical cancer cells. This evidence concerns the gene HLA-A and cervical cancer.